Alcohol Pharmacotherapy for HIV+ Prisoners
What is the purpose of this trial?
This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.
- 18 Years - N/A
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- August 2010
- Last Updated:
- April 29, 2015
- Study HIC#:
Clinicaltrials.gov ID: NCT01077310